September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Lipid nanoemulsion associated with paclitaxel as a new antiscarring agent in experimental glaucoma surgery
Author Affiliations & Notes
  • Vital P Costa
    Ophthalmology, University of Campinas, Sao Paulo, Brazil
  • Marcelo Occhiutto
    Ophthalmology, University of Campinas, Sao Paulo, Brazil
  • Fatima R. Freitas
    INCOR, University of Sao Paulo, Sao Paulo, Brazil
  • Patricia Picciarelli
    INCOR, University of Sao Paulo, Sao Paulo, Brazil
  • Raul Maranhao
    INCOR, University of Sao Paulo, Sao Paulo, Brazil
  • Footnotes
    Commercial Relationships   Vital Costa, Alcon (F), Alcon (C), Genom (F), Merck (F), Merck (C), New World Medical (F), Solx (F); Marcelo Occhiutto, None; Fatima Freitas, None; Patricia Picciarelli, None; Raul Maranhao, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2932. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Vital P Costa, Marcelo Occhiutto, Fatima R. Freitas, Patricia Picciarelli, Raul Maranhao; Lipid nanoemulsion associated with paclitaxel as a new antiscarring agent in experimental glaucoma surgery. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2932.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose : To investigate the effects of paclitaxel associated to lipid nanoemulsions (LDE-PTX) upon postoperative scarring in rabbits undergoing trabeculectomy.

Methods : Thirty-four New Zealand rabbits that underwent trabeculectomy were allocated to 4 groups: LDE-PTX/SC (n=9), treated with one intraoperative subconjunctival injection of LDE-PTX(1.5 mg); LDE-PTX/IV (n=9), treated with LDE-PTX (4mg/kg/day intravenously) at the end of the surgery and once a week for 3 weeks; MMC(n=9), treated with intraoperative 0.4 mg/mL mitomycin-C for 3 minutes; and control group (CTL, n=7), without treatment. Bleb characteristics, anterior chamber depth and intraocular pressure were evaluated over 4 weeks by a masked-observer. Bleb failure was defined when a flat, scarred, vascularized bleb was observed in association with a deep anterior chamber. Animals were sacrificed on day 28. Histologic analyses were performed to assess the amount of scarring and toxicity to the conjunctiva and ciliary body.

Results : Groups were similar with respect to intraocular pressure and anterior chamber depth during the 28-day observation period. LDE-PTX/SC,LDE-PTX/IVand MMCgroups showed greater bleb height than controls on days 14 and 21 (p<0.01). The median survival times were 14, 21, 28 and 28 days for the CTL, LDE-PTX/IV, LDE-PTX/SC and MMC groups, respectively. LDE-PTX/SC, LDE-PTX/IV and MMC showed significantly longer bleb survival times than CTL (p<0.001). There were no significant differences in survival times among the 3 treatment groups (p>0.05). LDE-PTX/SC,LDE-PTX/IV and MMC were equally effective in reducing fibrosis (p<0.001), number of blood vessels (p<0.001) and chronic inflammatory cells (p<0.001) at the surgical site. However, LDE-PTX/SC and LDE-PTX/IV treatments had lower conjunctival and ciliary body toxicity (p<0.001) compared to MMC.

Conclusions : Both LDE-PTX/SC and LDE-PTX/IV were effective in reducing the scarring process following trabeculectomy to the same extent as mitomycin C, but with considerably less toxicity to the conjunctiva and ciliary body. The novel preparation in both administration routes may offer promising results for wound healing modulation in the surgical treatment of glaucoma.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×